noscript

News and Announcements

QBiotics Raises $22.1m. ASX & Cochlear Chairman Joins Board

  • Published February 01, 2017 12:54PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

QLD based QBiotics, who are developing drugs targeting cancer and wound healing, raised a total of $22.1m in 2016.

Their Board has also been strengthened with the addition of Rick Holiday-Smith as Chairman (ASX; Cochlear) as well as Dr Bruce Robinson (Mayne Pharma) and Andrew Denver (Cochlear) as non-exec Directors.

ABOUT QBIOTICS

QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the veterinary market through the USA’s FDA-CVM.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now